Dr. Manish Patel
Claim this profileFlorida Cancer Specialists
Expert in Solid Tumors
Expert in Cancer
31 reported clinical trials
49 drugs studied
About Manish Patel
Education:
- Earned an MD from the University of Miami School of Medicine.
- Completed Internal Medicine Residency at Vanderbilt University, Nashville, TN.
- Undertook a Fellowship in Hematology/Oncology at the University of South Florida H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
Experience:
- Board-certified in Medical Oncology, Hematology, and Internal Medicine.
- Serves as the Director of Drug Development at Florida Cancer Specialists, focusing on early phase clinical studies in cancer treatment drugs and therapies.
- Principal investigator for numerous Phase 1 clinical trials in medical oncology and malignant hematology.
- Renowned speaker in oncology, presenting at national and international professional symposiums.
- Joined Florida Cancer Specialists in 2011, directing three Drug Development Units (DDUs) in partnership with Sarah Cannon.
Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
2Cancer
Global LeaderStage IV
MDM2 positive
TP53 negative
Affiliated Hospitals
Clinical Trials Manish Patel is currently running
ARTS-021
for Advanced Cancer
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Recruiting1 award Phase 1 & 2
Voyager V1 + Cemiplimab
for Melanoma
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Recruiting1 award Phase 2
More about Manish Patel
Clinical Trial Related2 years of experience running clinical trials · Led 31 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Manish Patel has experience with
- Pembrolizumab
- Cemiplimab
- Sitravatinib
- CC-99712
- ARTS-021
- BMS-986460
Breakdown of trials Manish Patel has run
Solid Tumors
Cancer
Ovarian Cancer
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Manish Patel specialize in?
Manish Patel focuses on Solid Tumors and Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Manish Patel currently recruiting for clinical trials?
Yes, Manish Patel is currently recruiting for 6 clinical trials in Sarasota Florida. If you're interested in participating, you should apply.
Are there any treatments that Manish Patel has studied deeply?
Yes, Manish Patel has studied treatments such as Pembrolizumab, Cemiplimab, Sitravatinib.
What is the best way to schedule an appointment with Manish Patel?
Apply for one of the trials that Manish Patel is conducting.
What is the office address of Manish Patel?
The office of Manish Patel is located at: Florida Cancer Specialists, Sarasota, Florida 34232 United States. This is the address for their practice at the Florida Cancer Specialists.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.